CCPA hemihydrate
Based on 2 publication(s) in Google Scholar
CCPA (2-Chloro-N6-cyclopentyladenosine) hemihydrate a highly selective A1 adenosine receptors agonist with a Ki of 0.4 nM. CCPA hemihydrate inhibits adenylate cyclase with an IC50 of 33 nM. CCPA hemihydrate exhibits anti-seizure and cardiacprotective activity. CCPA hemihydrate can be used for the research of seizure and myocardial infarction.
For research use only. We do not sell to patients.
- CAS No.: 1217443-91-8
- Formula: C15H20ClN5O4.1/2H2O
- Molecular Weight:378.81
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) CCPA hemihydrate
MoreAll Adenosine Receptor Isoforms
More
Biological Activity
CCPA hemihydrate potently binds to rat brain membrane A1 adenosine receptors with a Ki of 0.4 nM, demonstrating high A1 selectivity (Ki of 3900 nM for A2)[1].
CCPA hemihydrate acts as a full A1 adenosine receptor agonist to inhibit rat fat cell membrane adenylate cyclase with an IC50 of 33 nM, and shows an IC50 of 3500 nM for A2[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
CCPA (0.125 mg/kg; i.v.; 30 min before induction) hemihydrate reduces infarct size in a rabbit model of coronary artery occlusion-induced myocardial infarction[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1217443-91-8
-
Molecular Weight 378.81
-
Formula C15H20ClN5O4.1/2H2O
-
SMILES
ClC(N=C1NC2CCCC2)=NC3=C1N=CN3[C@H]4[C@H](O)[C@H](O)[C@@H](CO)O4.O.[0.5]
-
Synonyms
2-Chloro-N6-cyclopentyladenosine hemihydrate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Br J Pharmacol
An adenosinergic positive feedback loop extends pharmacological cardioprotection duration. [Abstract]2024 Dec;181(23):4920-4936. PMID: 39256947 -
bioRxiv
Molecular cloning of a novel, nervous system-specific RGS6 isoform lacking canonical G protein regulatory effects and with dominant negative actions. [Abstract]2026 May 12:2026.05.08.723811. PMID: 42182468
Purity & Documentation
References
[1]. Czuczwar S J. 2-Chloro-N 6-cyclopentyladenosine enhances the anticonvulsant action of carbamazepine in the mouse maximal electroshock-induced seizure model A[J]. Pharmacological reports, 2005, 57(787): 787-794. [Content Brief]
[2]. Tsuchida A, et al. Pretreatment with the adenosine A1 selective agonist, 2-chloro-N6-cyclopentyladenosine (CCPA), causes a sustained limitation of infarct size in rabbits[J]. Cardiovascular research, 1993, 27(4): 652-656. [Content Brief]
[3]. Lohse MJ, et al. 2-Chloro-N6-cyclopentyladenosine: a highly selective agonist at A1 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol. 1988;337(6):687-689. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
CCPA hemihydrate Related Classifications
HY-103185A Related Classifications
Powered by Bioz